AMP Annual Meeting | Conferences

Incorporating Genomics into Lymphoma Classification Can Improve Care

November 21, 2020

The incorporation of genomics into the classification and treatment decision-making process for lymphomas is possible; however, many obstacles have prevented the incorporation of sequencing into standard practice, according to Sandeep Dave, MD.

Big Data–Based Tools Support Cancer Clinical Decision-Making

November 20, 2020

Clinicians are increasingly looking to big data and electronic medical records (EMR) data integration tools in support of clinical decision-making questions and processes for improved access and care for their patients with cancer.

Low-Level EGFR Variants in NSCLC Detectable by Liquid Biopsy Assays

November 20, 2020

Target capture next-generation sequencing, MassARRAY, and real-time quantitative polymerase chain reaction all effectively detected low frequency somatic epidermal growth factor receptor mutations in cell-free circulating tumor DNA from individuals with non–small cell lung cancer , according to a presentation at the AMP 2020 Annual Meeting and Expo.

Molecular Testing With Universal Method Comparable to Traditional Method in Hereditary Solid Tumors

November 17, 2020

In an interview with Targeted Oncology during the 2020 Association for Molecular Pathology Annual Meeting, Ozge Ceyhan-Birsoy, PhD, discussed genetic testing methods for patients with hereditary predisposition and the molecular research underway at MSKCC to improve testing in this patient population.

Sequencing TP53 Mutations in Myeloid Neoplasms

November 17, 2020

Routine testing for the presence of TP53 mutations in myeloid neoplasms by sequencing will become an important part of routine care as TP53-targeting agents become available, according to a poster presented at the Association for Molecular Pathology 2020 Annual Meeting and Expo.

Comparing Impact of Panel Composition on Tumor Mutational Burden Calculation

November 15, 2019

Nicholas Bevins, MD, PhD, discusses the results from an in silico comparison of frequently used next-generation sequencing panels. The analysis aimed to identify the impact of the panel composition on tumor mutational burden calculations. Results from the analysis were presented in a poster at the 2019 Association for Molecular Pathology Annual Meeting and Expo.

DNA-Based NGS Panel Accurately Detects MET Exon 14 Skipping Mutations in NSCLC

November 14, 2019

In an interview with Targeted Oncology, Willemina R. Geurts-Giele, PhD, discussed the accuracy of detecting MET exon 14 skipping mutations in patients with NSCLC with DNA-based NGS panels. These findings were presented at The Association for Molecular Pathology Annual Meeting and Expo.